Antitussive Use in Patients with Inadequately Controlled Moderate-to-Severe Asthma: A Post Hoc Analysis of the Omalizumab EXTRA Trial

Figures & data

Table 1 Antitussive Use in Patients with Severe Asthma During the Treatment Period: Patients with No Antitussive Use at Baseline

Number of Antitussives Used, n (%)	Placebo (n = 403)	Omalizumab (n = 411)
0	336 (83.4%)	363 (88.3%)
1	53 (13.2%)	29 (7.1%)
2	9 (2.2%)	10 (2.4%)
3	4 (1.0%)	7 (1.7%)
≥4	1 (0.2%)	2 (0.5%)
Adjusted rate (48 weeks)^a	0.25 (0.1846, 0.3361)	0.22 (0.1570, 0.2950)
Ratio of rates (95% CI)^b	0.8640 (0.5692, 1.3115)

Notes: If more than one antitussive was used at the same time this was considered a single event. ^aPoisson regression with over-dispersion model including terms for treatment, concomitant asthma medication strata at baseline, dosing regimen. ^bRate ratio: omalizumab vs placebo.

Figure 1 Type of Antitussives Used During the Treatment Period.

Abbreviation: OMA, omalizumab.